Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 5,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Lung Cancer Clear all

Conditions: Non-small Cell Lung Cancer (NSCLC), Chronic Obstructive Pulmonary Disease (COPD)
Interventions: education, rehabilitation, pedometer, surgery; Other · Procedure · Device
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Jacksonville, Florida • Chicago, Illinois • Detroit, Michigan + 3 more

Conditions: Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
Interventions: Carfilzomib, Irinotecan; Drug
Lead sponsor: Cancer Research and Biostatistics Clinical Trials Consortium; Network
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 8
States / cities: Goodyear, Arizona • Lexington, Kentucky • Louisville, Kentucky + 5 more

Conditions: Carcinoma, Non-Small Cell Lung
Interventions: axitinib, chemotherapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 12
States / cities: Huntsville, Alabama • Atlanta, Georgia • Decatur, Georgia + 8 more

Conditions: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Interventions: Exhaled Breath Sampling; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Colon, Cancer Skin, Cancer of Cervix, Cancer, Metastatic, Cancer of Larynx, Cancer of Neck, Cancer of Lung, Cancer of Brain and Nervous System, Cancer of Vulva, Disseminated, Cancer of Pancreas, Sarcoma, GIST, Small-cell Lung Cancer, Adenocarcinoma Lung, Cancer of Prostate, Cancer, Advanced, Adrenal Cancer, Testicular Cancer, Uterine Cancer, Bronchoalveolar Cell Lung Cancer, Cancer Unknown Primary, Glioblastoma Multiforme, Oligodendroglioma, Breast Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Cancer, Other, Cancer, Anal, Melanoma, Cancer, Bile Duct, Cancer, Bladder, Cancer Cords Vocal, Cancers Cell Neuroendocrine, Cancer Differentiated Poorly, Cancer, Anaplastic Thyroid
Interventions: Not listed
Lead sponsor: SpeciCare; Industry
Eligibility: 1 Month to 99 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Gainesville, Georgia

Conditions: Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
Interventions: Multi-analyte Blood Test; Diagnostic Test
Lead sponsor: Helio Genomics; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Timeline: 2019 – 2028
U.S. locations: 7
States / cities: Redondo Beach, California • Coon Rapids, Minnesota • Fridley, Minnesota + 4 more

Conditions: Lung Cancer, Cancer of the Lung
Interventions: Pink and Pearl Campaign; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 20 Years and older
Enrollment: 5,515 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lung Cancer Screening
Interventions: Educational Video about LDCT lung cancer screening, A culturally tailored shared decision-making tool, Flip chart, Navigation support; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 50 Years to 80 Years · Male only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: cisplatin, etoposide, erlotinib hydrochloride, radiation therapy, docetaxel, paclitaxel, carboplatin, laboratory biomarker analysis; Drug · Radiation · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Adenocarcinoma
Interventions: Immunotherapeutic Agents, Ablation; Drug · Device
Lead sponsor: Gary Onik MD; Individual
Eligibility: 19 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Erlotinib, Onartuzumab (MetMab), Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 56
States / cities: Chandler, Arizona • Hayward, California • Modesto, California + 47 more

Conditions: Lung Cancer, Non-small Cell Lung Cancer, Metastatic Lung Cancer, Head and Neck Cancer, Metastatic Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Resectable Head and Neck Squamous-cell Carcinoma
Interventions: PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-1 inhibitor monotherapy - 2 cycles before 12:00PM, PD-1 inhibitor monotherapy - 2 cycles after 3 PM; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Non-Small Cell Lung Cancer
Interventions: bevacizumab, placebo, erlotinib HCl; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 177
States / cities: Mobile, Alabama • Fort Smith, Arizona • Scottsdale, Arizona + 160 more

Conditions: Oncologic Complications, Quality of Life, Nutrition Poor, Head and Neck Cancer, Lung Cancer, Pancreatic Cancer
Interventions: Dexamethasone, Dronabinol, Mirtazapine, Nutrition Intervention; Drug · Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pancreatic Cancer, Non-Small-Cell Lung Cancer
Interventions: Dignity Therapy; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 19 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions: Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 115
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more

Conditions: Lung Cancer
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 120 Years
Enrollment: 15,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Lung Cancer
Interventions: BAY 43-9006, Paclitaxel, Carboplatin, Bevacizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastric Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Small Cell Lung Cancer
Interventions: trastuzumab, paclitaxel, recombinant interleukin-12; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Non-small Cell Lung Cancer
Interventions: Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 26
States / cities: Sacramento, California • Aurora, Colorado • New Haven, Connecticut + 22 more

Conditions: Advanced Solid Tumors
Interventions: BMS-986490, Bevacizumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Los Angeles, California • Grand Rapids, Michigan • Hackensack, New Jersey + 1 more

Conditions: Metastatic Cancer, Cancer, Solid Tumors
Interventions: BIND-014; Drug
Lead sponsor: BIND Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 6
States / cities: Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 3 more

Conditions: Lung Cancer
Interventions: educational intervention, questionnaire administration, end-of-life treatment/management, psychosocial assessment and care, quality-of-life assessment; Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Duarte, California

Conditions: Stage IV Non-Small Cell Lung Cancer
Interventions: Stereotactic Body Radiation Therapy, Maintenance chemotherapy; Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Pulmonary Rehabilitation Before Lung Cancer Resection

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer

Breath Analysis for Evaluation of Radiation Exposure in Lung Cancer Patients Treated With Radiation

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital

The SHARED, Project, Lung Cancer Screening for African American Men (AAM)

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Effects of Infusion Timing on Treatment Response in Solid Tumors

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

Nutrition and Pharmacological Algorithm for Oncology Patients Study

Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

DNA Analysis of Blood and Tissue From Patients With Lung Cancer

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Palliative Care Teaching Sessions for Family Caregivers of Patients With Non-Small Cell Lung Cancer

Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial